Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NPBWR1 | P48145 | 3/20 | 0.34 |
| ▸ | MCHR1 | Q99705 | 1/20 | 0.32 |
| ▸ | P2RX7 | Q99572 | 1/20 | 0.31 |
| ▸ | ABCC1 | P33527 | 1/20 | 0.30 |
| ▸ | ABCG2 | Q9UNQ0 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31688010 | 0.89 | NPBWR1 (0.36) | NPBWR1MCHR1P2RX7ABCC1ABCG2 | |
| SCHEMBL31688006 | 0.87 | NPBWR1 (0.36) | NPBWR1MCHR1P2RX7ABCC1ABCG2 | |
| SCHEMBL27192017 | 0.86 | P2RX7 (0.32) | NPBWR1P2RX7 | |
| SCHEMBL31688009 | 0.83 | NPBWR1 (0.36) | NPBWR1MCHR1P2RX7ABCC1ABCG2 | |
| SCHEMBL31688018 | 0.78 | SCN9A (0.32) | NPBWR1 | |
| SCHEMBL31687992 | 0.77 | PRKDC (0.30) | — | |
| SCHEMBL31688011 | 0.76 | HSD17B10 (0.38) | NPBWR1MCHR1P2RX7ABCC1ABCG2 | |
| SCHEMBL27192264 | 0.74 | P2RX7 (0.34) | NPBWR1P2RX7 | |
| SCHEMBL27192206 | 0.73 | — | — | |
| SCHEMBL27192020 | 0.73 | P2RX7 (0.34) | NPBWR1P2RX7 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250296936-A1 | SARS-COV2 MAIN PROTEASE INHIBITORS | GILEAD SCIENCES, INC. | 2025-09-25 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250296936-A1 | SARS-COV2 MAIN PROTEASE INHIBITORS | ACE2, TMPRSS2, ACE | NPBWR1 4288/4885MCHR1 4727/4885P2RX7 4279/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.